Author

Jamie T. Ta

Observed names: J. Ta, Jamie T Ta, Jamie Ta, Ta JT, Ta, Jamie, Ta, Jamie T.

Observed institutions: Genentech, University of Washington, AbbVie (United States), University of California San Diego, Health Economics and Outcomes Research (United Kingdom), National Pharmaceutical Council

OpenAlex ID: A5113065563

Epidemiology of Huntington’s Disease in the United States Medicare and Medicaid Populations

2022 · Alex Exuzides, Sheila R. Reddy, et al. · Neuroepidemiology · 28

PDF

Direct Costs Incurred Among Women Undergoing Surgical Procedures to Treat Uterine Fibroids

2020 · Amanda Harrington, Nicole G. Bonine, et al. · Journal of Managed Care & Specialty Pharmacy · 16

PDF

Is There a Relationship Between Part D Medication Adherence and Part C Intermediate Outcomes Star Ratings Measures?

2016 · Jamie T. Ta, Sara C. Erickson, et al. · Journal of Managed Care & Specialty Pharmacy · 16

PDF

Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder

2021 · Jamie T Ta, Sean D Sullivan, et al. · Journal of Managed Care & Specialty Pharmacy · 15

PDF

Healthcare utilization and cost burden of Huntington’s disease among Medicare beneficiaries in the United States

2021 · Alex Exuzides, Sheila R. Reddy, et al. · Journal of Medical Economics · 11

Healthcare resource utilization and costs in individuals with Huntington’s disease by disease stage in a US population

2022 · Alex Exuzides, Tu My To, et al. · Journal of Medical Economics · 6

PDF

Real-world effectiveness of cariprazine in major depressive disorder and bipolar I disorder in the United States

2025 · Roger S. McIntyre, Mousam Parikh, et al. · Journal of Medical Economics · 5

PDF

Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington’s disease: a claims‑based retrospective cohort study

2023 · Tu My To, Jamie T. Ta, et al. · Journal of Medical Economics · 4

PDF

Health care resource utilization and costs among individuals with vs without Huntington disease in a US population

2022 · Tu My To, Alex Exuzides, et al. · Journal of Managed Care & Specialty Pharmacy · 4

PDF

Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making

2020 · Shuxian Chen, Jennifer Graff, et al. · Journal of Managed Care & Specialty Pharmacy · 4

PDF

Healthcare Resource Utilization and Costs of Patients with Relapsed/Refractory Follicular Lymphoma Receiving 3 or More Lines of Therapy

2021 · Matthew J. Matasar, Sheila Shapouri, et al. · Blood · 3

The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States

2025 · Prakash S. Masand, Mousam Parikh, et al. · Journal of Medical Economics · 2

Real-World Disability Outcomes Among Patients Treated with Cariprazine vs Other Atypical Antipsychotics as Adjunctive Treatment for Major Depressive Disorder

2025 · Prakash Masand, Mousam Parikh, et al. · ClinicoEconomics and Outcomes Research · 1

PDF

Treatment Patterns and Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated in Routine Clinical Practice in the US with Three or More Lines of Therapy

2021 · Jamie T. Ta, Stella Arndorfer, et al. · Blood · 1

Healthcare utilization and costs associated with first-line treatment with obinutuzumab- and rituximab-based regimens for follicular lymphoma.

2021 · Jamie T. Ta, Tu My To, et al. · Journal of Clinical Oncology · 1

Real-world treatment patterns and outcomes in patients with follicular lymphoma in the United States.

2021 · Jamie T. Ta, Taha Itani, et al. · Journal of Clinical Oncology · 1

Real-World Assessment of Healthcare Resource Utilization-Defined Manic and Depressive Events Among Patients with Bipolar I Disorder Treated with Cariprazine Versus Aripiprazole

2026 · Roger S. McIntyre, Mousam Parikh, et al. · Advances in Therapy

PDF

Healthcare Resource Utilization and Costs Associated with Obinutuzumab Plus Bendamustine Versus Rituximab Plus Bendamustine for First-Line Treatment of Follicular Lymphoma

2021 · Tu My To, Jamie T. Ta, et al. · Blood

PND34 Healthcare Utilization and Costs at End-of-Life Among US Medicaid Beneficiaries with Huntington's Disease

2021 · S. Reddy, A. Exuzides, et al. · Value in Health

Burden of Illness Among US Medicare Beneficiaries with Late-Onset Huntington’s Disease (2255)

2021 · Jamie Ta, Sheila Reiss Reddy, et al. · Neurology

Pcn35 "net Health Benefit” - Asco Vs. I.c.e.r. Value Frameworks: Are We Talking About the Same Thing?

2019 · J. Ta, B. Devine, et al. · Value in Health

PDF

Healthcare Resource Utilization and Costs Associated with Non-Adherence to Pharmacotherapy for Major Depressive Disorder

2019 · Jamie T. Ta · ResearchWorks at the University of Washington (University of Washington)

PDF

Works count: 26

Citation count: 118

H-index: 6

I10-index: 5